Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 22nd June 2016
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Project to reduce use of animals in vaccine production
Lab mouse
The project could significantly reduce the use of animals in routine vaccine production.
VAC2VAC takes One Health approach to replacing traditional testing methods 

A project which could significantly reduce the use of animals in routine vaccine production will unite some of Europe’s largest pharmaceutical companies.

Funded by the Innovative Medicines Initiative (IMI2), the VAC2VAC project aims to provide data to support the ‘Consistency Approach’ for quality control of vaccines.  Currently, quality control for final products relies on in vivo methods.

A host of organisations from veterinary and human vaccine industry are collaborating in the project, including Zoetis, GlaxoSmithKlein (GSK) and Merial.

To achieve their goal, the organisations will develop, optimise and evaluate physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies.

Noting the importance of this project, Denis Lambrigts from GSK said: “The VAC2VAC project provides a unique platform to support the transition away from in vivo batch release testing for vaccines.

“It brings together both the human and veterinary pharmaceutical industry along with academia and regulators, to build a platform for the development, validation and regulatory acceptance of alternative approaches.

“For industry this is a very positive One Health approach to the challenge of replacement of the long established in vivo test methods and all companies involved are committed to the success off this project.”

Prof. Conrad Hendriksen from Intravacc, one of the key promoters of the project, added: “VAC2VAC takes into account both vaccine safety and animal welfare.

“It will allow us to move away from the traditional paradigm of vaccine batch release testing and to accelerate the introduction of a new paradigm based on innovative non-animal techniques”.

The project is expected to end in 2021 at a total cost of €15.98 million. 

Become a member or log in to add this story to your CPD history

RUMA CA&E extends survey deadline

News Story 1
 RUMA CA&E has extended the deadline for its online survey into vaccine availability.

Vets, SQPs, retailers and wholesalers will now have until Friday, 26 September at 5pm to submit their response.

The survey aims to further understanding into the vaccine supply challenges faced by the sector. It will also consider the short and long term impacts of disruption issues.

Insights are anonymous, and will be shared with industry stakeholders and government bodies.

The survey can be accessed here. 

Click here for more...
News Shorts
Dechra launches checklist for veterinary sustainability

Global animal health specialist Dechra has announced the world's first Veterinary Green Theatre Checklist (VGTC) to help make surgery more sustainable.

Endorsed by leading veterinary organisations, including the BEVA, BVNA and RCVS Knowledge, the checklist is designed to reduce the environmental footprint of veterinary care, while supporting better animal health outcomes.

The checklist was launched at the World Congress of Veterinary Anaesthesia and Analgesia in Paris and will be followed by an internal training and awareness campaign. For more information, visit dechra.com